Overview
Dufrane received his medical degree and doctorate in biomedical sciences from UCLouvain and was previously head of the Musculoskeletal Tissue Bank and Tissue/Cells Therapy Centre at Saint-Luc University Hospital in Brussels. He co-founded Novadip in 2013 and joined full-time in 2015. The company's 3M3 tissue regeneration platform uses adipose-derived stem cells, and has raised EUR 88 million in total funding including EUR 40 million in a 2022 round and a subsequent EIB venture debt tranche under InvestEU.
Career history
In the news
- Close to €70m raised to avoid amputations that cost close to €1m each. NEW EPISODE: Denis Dufrane, Founder & CEO of NOVADIP Biosciences S.A. ⚡ Novadip turns your own fat tissue into 3D bone, starting with kids. That €1m covers the three years after an amputation: prosthesis and multiple reconstructive surgeries. There is also close to 10 years of psychological follow-up, and as Denis says, a prosthesis will never be your limb. Denis is an MD, PhD who spent 15 years at Cliniques universitaires Saint-Luc in Brussels. He treated 15
- I'm not a fan of the definition or the justification of a team building since for me, a team is built on the daily trust between peoples, skills and experts for a common goal. But it's a so nice to enjoy time and fun as a team to give a positive energy for our next objectives Let's go Novadip #Novadip
- Many thanks to our shareholders for their continued support in our mission to transform the lives of patients without any alternatives to amputation. While our lead indication targets a rare pediatric disease, with market approval expected in 2028, our technology is also being developed to benefit a much broader population of adult patients. Our greatest value driver, our reward is to see the smile on the face of a young patient as they walk again, run again, play with friends again, and regain the simple joys of a normal life.
- Thanks to Prof Thierry Béggé (Hôpital Antoine-Béclère, Paris) for the the opportunity to present our unique technology for the treatment of critical size bone defect in the prestigious congress of the European Society of Tissue Regeneration in Orthopedics and Trauma. #Bone #Novadip
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.